This summary was created by AI, based on 1 opinions in the last 12 months.
Owens & Minor (OMI-N) has emerged as a leading name in the small-cap health sector, attracting attention from analysts who regard it as a top pick in this category. During the COVID-19 pandemic, the company successfully utilized the Paycheck Protection Program (PPP) and subsequently expanded its operations by acquiring two companies focusing on home healthcare. As a result, Owens & Minor has reported impressive sales growth of 24% in 2023, despite the decline in PPP funds. Looking forward, the company projects a robust annual growth rate of 20% in earnings per share (EPS), indicating a positive outlook for future performance. Overall, the company's strategic moves and growth prospects underscore its strong position in the evolving healthcare sector.
Owens & Minor is a American stock, trading under the symbol OMI-N on the New York Stock Exchange (OMI). It is usually referred to as NYSE:OMI or OMI-N
In the last year, 1 stock analyst published opinions about OMI-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Owens & Minor.
Owens & Minor was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Owens & Minor.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Owens & Minor published on Stockchase.
On 2025-02-11, Owens & Minor (OMI-N) stock closed at a price of $8.48.
A top pick in smallcap health. They made PPP during Covid then bought two companies in home healthcare. Sales rose 24% in 2023, though PPP declined. They just projected EPS growing 20% annually.